Topotecan
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Topotecan: From Ovarian Cancer to Female Breast Carcinoma
One-Sentence Summary
Topotecan is a topoisomerase I inhibitor originally developed for relapsed ovarian cancer and later extended to small cell lung cancer and cervical cancer. The TxGNN model predicts it may also be effective for Female Breast Carcinoma, with 5 clinical trials and 20 publications currently informing this direction — though the trial evidence is mixed in strength and relevance.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Ovarian cancer / small cell lung cancer / cervical cancer (well-established international indications; no formal local regulatory record in this evidence pack) |
| Predicted New Indication | Female Breast Carcinoma |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L2 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
A dedicated MOA record is not available in this evidence pack (flagged as a High-severity data gap, DG002). However, the repurposing rationale attached to this prediction and the supporting literature consistently describe topotecan as a semisynthetic camptothecin derivative that acts as a topoisomerase I inhibitor: it stabilizes the DNA–Topo I cleavage complex, causing single-strand DNA breaks and replication fork collapse, which triggers apoptosis preferentially in rapidly dividing cells.
This is a broad-spectrum cytotoxic mechanism, not one restricted to gynecologic malignancy. Ovarian cancer (the drug’s classic indication) and breast cancer share overlapping biology — including BRCA1/2-related DNA-repair deficiency and high proliferative subtypes — which provides mechanistic plausibility for cross-tumor activity. Preclinical work specifically links topotecan to triple-negative breast cancer (TNBC), the most aggressive and highest-proliferation subtype, via targets such as TFDP1 and MYC-driven synthetic lethality.
Clinically, this plausibility is only partially confirmed: a completed CALGB Phase II trial and several small Phase I/II studies tested topotecan directly in breast cancer, but results are dated (1990s–2000s), come from small cohorts, and predate modern subtype-directed trial design. No confirmatory Phase III trial in breast cancer currently exists in this evidence pack.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00006032 | Phase 2 | Terminated | N/A | TIME regimen (topotecan + ifosfamide/mesna + etoposide) followed by autologous stem cell rescue in metastatic breast cancer; trial terminated, no efficacy conclusion available |
| NCT02282020 | Phase 3 | Completed | 266 | Olaparib vs. physician’s-choice chemotherapy in gBRCA-mutated, platinum-sensitive relapsed ovarian cancer; large completed trial, but topotecan’s specific role in the comparator arm is not detailed in the summary |
| NCT04739800 | Phase 2 | Active, not recruiting | 120 | Durvalumab + olaparib + cediranib triplet vs. standard-of-care chemotherapy in platinum-resistant recurrent ovarian/peritoneal/fallopian cancer; topotecan is a comparator/backbone agent, not the primary study drug |
| NCT02419495 | Phase 1 | Terminated | 221 | Selinexor combined with standard chemo/immunotherapy regimens (including topotecan) in advanced malignancies; safety-focused, terminated early |
| NCT04279509 | N/A | Unknown | 35 | Patient-derived organoid high-throughput drug screening to guide chemotherapy selection in refractory solid tumors; not a direct treatment trial |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10362325 | 1999 | Phase II Trial (CALGB) | American Journal of Clinical Oncology | Topotecan monotherapy in advanced breast cancer after prior chemotherapy; 40 of 53 patients evaluable — earliest direct efficacy data in this population |
| 11455218 | 2001 | Cohort/Pilot | Onkologie | Pilot study of topotecan as primary chemotherapy for breast cancer patients with brain metastases |
| 9413954 | 1997 | Phase 1/2 Trial | British Journal of Cancer | Continuous infusional topotecan in advanced breast cancer and NSCLC; no evidence of increased efficacy over standard dosing |
| 21514634 | 2011 | Phase II RCT | Gynecologic Oncology | Lapatinib + topotecan in platinum-refractory/resistant ovarian/peritoneal carcinoma (note: population is ovarian, not breast, cancer despite indexing) |
| 40300683 | 2025 | Preclinical/Mechanistic | International Journal of Biological Macromolecules | TFDP1 identified as a druggable target for topotecan in triple-negative breast cancer |
| 26623560 | 2015 | Preclinical | Oncotarget | Metronomic topotecan + pazopanib shows potent efficacy in preclinical models of primary and metastatic TNBC |
| 39657238 | 2024 | Preclinical | ACS Applied Materials & Interfaces | Biomimetic topotecan + anti-VEGF gene nanoparticle combination for metastatic breast cancer |
| 31408695 | 2019 | Preclinical | Pharmacological Research | Daidzein enhances topotecan’s anticancer effect and reverses BCRP-mediated drug resistance in breast cancer |
| 37987734 | 2023 | Preclinical/Mechanistic | Cancer Research | Topoisomerase I inhibition induces synthetic lethality via R-loop accumulation in MYC-driven breast cancer cell lines |
| 9445630 | 1997 | Review | Gynäkologisch-Geburtshilfliche Rundschau | Review of new cytotoxic agents (including topotecan) in breast carcinoma therapy |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (Topoisomerase I inhibitor, camptothecin derivative) |
| Myelosuppression Risk | High — dose-limiting toxicity reported in related trial data (e.g., PMID 8617580: median nadir neutrophil count 1.55 cells/mm³, platelet count 20,500/mm³) |
| Emetogenicity Classification | Low to moderate (typical for topoisomerase I inhibitor class) |
| Monitoring Items | CBC with differential (neutrophils, platelets), renal function (drug is renally cleared), signs of infection |
| Handling Protection | Must be handled per cytotoxic/hazardous drug handling regulations |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: A Blocking-severity data gap (DG001 — TFDA warnings/contraindications unavailable) prevents even an initial safety review (S1), and the breast cancer efficacy evidence, while mechanistically plausible, rests on small, dated Phase I/II trials rather than confirmatory Phase III data; several cited trials/publications are also indexed with likely disease-label mismatches (e.g., NCT02282020 and PMID 21514634 concern ovarian, not breast, cancer) and need manual verification before further scoring.
To proceed, the following is needed:
- TFDA (or equivalent) approved label: warnings, contraindications, and dosing information
- Confirmed mechanism of action documentation from DrugBank
- Manual re-verification of disease-label matches for NCT02282020, NCT04739800, and PMID 21514634
- Drug–drug interaction (DDI) data, currently unavailable
- Assessment of whether any ongoing/planned Phase III trial specifically targets breast cancer (particularly TNBC) populations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.